Liraglutide: adverse events and evidence limits
A 56-week subcutaneous liraglutide trial enrolled adults without type 2 diabetes with obesity, or overweight plus hypertension or dyslipidemia. Common events were mild or moderate nausea and diarrhea; serious events occurred in both arms. [1]
The inspected abstract does not establish each event’s causality or a particular catalog reagent’s safety. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Nausea | Adults without type 2 diabetes with obesity, or overweight plus hypertension or dyslipidemia; subcutaneous liraglutide, 56 weeks | Among the most commonly described events, mild or moderate; no percentage given in the abstract | [1] |
| Diarrhea | The same participants | Among the most commonly described events, mild or moderate; no percentage given in the abstract | [1] |
| Serious events | The same participants | Occurred in both arms of the trial; no frequency given in the abstract | [1] |
References
- Xavier Pi-Sunyer et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management https://doi.org/10.1056/NEJMoa1411892.